
Guerbet S.A (GBT) | Financial Analysis & Statements
Guerbet S.A. | Mid-cap | Healthcare
Guerbet S.A. | Mid-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
1.0B
Total Liabilities
645.7M
Shareholders Equity
391.6M
Debt to Equity
1.65
Cash Flow Metrics
Revenue & Profitability Trend
Guerbet S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 851.1M | 795.7M | 769.5M | 735.9M | 716.7M |
Cost of Goods Sold | 224.4M | 206.8M | 211.2M | 218.4M | 192.0M |
Gross Profit | 626.7M | 588.9M | 558.3M | 517.5M | 524.7M |
Gross Margin % | 73.6% | 74.0% | 72.6% | 70.3% | 73.2% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 14.8M | 15.7M | 16.4M | 13.6M | 15.7M |
Other Operating Expenses | 207.8M | 190.9M | 182.4M | 164.4M | 159.5M |
Total Operating Expenses | 222.6M | 206.6M | 198.8M | 178.0M | 175.2M |
Operating Income | 48.8M | 39.2M | 42.9M | 39.4M | 42.8M |
Operating Margin % | 5.7% | 4.9% | 5.6% | 5.4% | 6.0% |
Non-Operating Items | |||||
Interest Income | 283.0K | 123.0K | 34.0K | 59.0K | 83.0K |
Interest Expense | 20.5M | 10.6M | 4.6M | 5.3M | 4.9M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 19.4M | 30.8M | -28.4M | 29.0M | 22.2M |
Income Tax | 5.9M | 8.6M | 12.7M | -3.7M | 4.0M |
Effective Tax Rate % | 30.4% | 28.0% | 0.0% | -12.6% | 18.0% |
Net Income | 13.5M | 22.2M | -41.1M | 32.6M | 18.2M |
Net Margin % | 1.6% | 2.8% | -5.3% | 4.4% | 2.5% |
Key Metrics | |||||
EBITDA | 114.3M | 101.2M | 146.8M | 91.3M | 90.1M |
EPS (Basic) | - | €1.75 | €-3.25 | €2.59 | €1.45 |
EPS (Diluted) | - | €1.75 | €-3.25 | €2.58 | €1.44 |
Basic Shares Outstanding | - | 12641115 | 12616390 | 12616390 | 12599494 |
Diluted Shares Outstanding | - | 12641115 | 12616390 | 12616390 | 12599494 |
Income Statement Trend
Guerbet S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 50.2M | 51.3M | 41.7M | 115.7M | 96.7M |
Short-term Investments | 36.2M | 41.5M | 41.2M | 42.9M | 33.2M |
Accounts Receivable | 172.9M | 149.5M | 121.2M | 118.8M | 111.0M |
Inventory | 301.2M | 305.2M | 272.5M | 202.0M | 204.6M |
Other Current Assets | 2.1M | 9.0M | 10.5M | 6.0M | 12.2M |
Total Current Assets | 590.0M | 581.6M | 509.7M | 495.5M | 468.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | 111.1M | 104.0M | 99.5M | 90.8M | 86.2M |
Goodwill | 135.5M | 125.9M | 125.4M | 228.4M | 228.1M |
Intangible Assets | 77.9M | 68.3M | 70.4M | 148.8M | 148.4M |
Long-term Investments | - | 900.0K | 900.0K | - | - |
Other Non-Current Assets | - | - | - | 1.0K | 1.0K |
Total Non-Current Assets | 447.3M | 443.6M | 430.0M | 505.4M | 477.1M |
Total Assets | 1.0B | 1.0B | 939.6M | 1.0B | 945.7M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 95.1M | 92.9M | 103.7M | 81.0M | 64.4M |
Short-term Debt | 44.5M | 12.7M | 33.4M | 33.4M | 34.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | -2.0K | -1.0K |
Total Current Liabilities | 254.5M | 229.2M | 239.6M | 236.9M | 200.2M |
Non-Current Liabilities | |||||
Long-term Debt | 350.6M | 374.0M | 278.4M | 299.1M | 317.5M |
Deferred Tax Liabilities | 6.4M | 9.4M | 9.9M | 15.2M | 14.8M |
Other Non-Current Liabilities | 1.0K | -1.0K | - | - | - |
Total Non-Current Liabilities | 391.2M | 417.7M | 320.5M | 358.9M | 377.7M |
Total Liabilities | 645.7M | 647.0M | 560.1M | 595.7M | 578.0M |
Equity | |||||
Common Stock | 12.6M | 12.6M | 12.6M | 12.6M | 12.6M |
Retained Earnings | 16.1M | 23.9M | -41.1M | 32.6M | 18.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 391.6M | 378.3M | 379.6M | 405.1M | 367.8M |
Key Metrics | |||||
Total Debt | 395.1M | 386.8M | 311.9M | 332.5M | 352.1M |
Working Capital | 335.5M | 352.4M | 270.1M | 258.6M | 268.3M |
Balance Sheet Composition
Guerbet S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 13.5M | 22.2M | -41.1M | 32.6M | 18.2M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 717.0K | 205.0K | -399.0K | 610.0K | -1.3M |
Working Capital Changes | -14.1M | -54.1M | -80.5M | -2.9M | 28.0M |
Operating Cash Flow | 20.6M | -21.1M | -117.5M | 35.6M | 49.7M |
Investing Activities | |||||
Capital Expenditures | -30.8M | -40.8M | -42.6M | -36.7M | -38.1M |
Acquisitions | 0 | -2.7M | 0 | - | -5.9M |
Investment Purchases | -1.2M | -2.4M | -3.5M | -7.4M | -1.5M |
Investment Sales | 2.4M | 973.0K | 0 | 1.3M | 7.1M |
Investing Cash Flow | -29.7M | -48.2M | -49.4M | -41.5M | -44.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -6.3M | -6.3M | -10.7M | -8.8M | -8.8M |
Debt Issuance | 13.3M | 445.5M | 2.4M | 6.6M | 7.3M |
Debt Repayment | -14.1M | -383.9M | -35.7M | -34.4M | -40.6M |
Financing Cash Flow | -7.1M | 55.4M | -44.0M | -36.0M | -42.0M |
Free Cash Flow | 24.2M | -26.6M | -20.1M | 67.0M | 60.8M |
Net Change in Cash | -16.2M | -13.9M | -210.9M | -41.9M | -36.6M |
Cash Flow Trend
Guerbet S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.54
Forward P/E
6.38
Price to Book
0.67
Price to Sales
0.31
PEG Ratio
6.38
Profitability Ratios
Profit Margin
1.89%
Operating Margin
4.34%
Return on Equity
3.50%
Return on Assets
2.96%
Financial Health
Current Ratio
2.32
Debt to Equity
100.91
Beta
0.79
Per Share Data
EPS (TTM)
€1.27
Book Value per Share
€31.28
Revenue per Share
€67.53
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
gbt | 265.9M | 16.54 | 0.67 | 3.50% | 1.89% | 100.91 |
Eurobio Scientific | 251.9M | 64.36 | 1.41 | 2.26% | 2.58% | 5.46 |
Affluent Medical | 53.9M | -3.72 | 1.75 | -48.69% | -275.50% | 0.54 |
Median Technologies | 39.8M | -1.53 | - | 74.31% | -109.93% | -0.98 |
Novacyt S.A | 31.3M | -0.75 | 0.65 | -57.28% | -212.73% | 24.81 |
Diagnostic Medical | 26.6M | -9.50 | 2.16 | -20.20% | -5.90% | 141.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.